Vantage Consulting Group’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-12,005
Closed -$208K 214
2023
Q3
$208K Buy
12,005
+389
+3% +$8.11K 0.14% 179
2023
Q2
$242K Buy
11,616
+1,053
+10% +$22.9K 0.14% 143
2023
Q1
$248K Buy
10,563
+1,607
+18% +$43.1K 0.14% 159
2022
Q4
$250K Buy
8,956
+341
+4% +$8.72K 0.15% 127
2022
Q3
$202K Buy
8,615
+1,830
+27% +$55.3K 0.12% 191
2022
Q2
$229K Buy
6,785
+377
+6% +$13.2K 0.13% 161
2022
Q1
$224K Sell
6,408
-2,654
-29% -$90.8K 0.09% 183
2021
Q4
$276K Buy
9,062
+1,912
+27% +$62.3K 0.07% 144
2021
Q3
$234K Sell
7,150
-478
-6% -$15.3K 0.05% 157
2021
Q2
$231K Buy
+7,628
New +$251K 0.04% 164

Other funds holding OGN

Vantage Consulting Group's OGN Position: Q4 2023 in Review

Vantage Consulting Group sold out of Organon & Co (OGN) in Q4 2023, closing a stake of 12,005 shares — an estimated $208K sold.

Vantage Consulting Group first reported a position in OGN in Q2 2021 and held it in 10 quarters. The position peaked at $276K in Q4 2021. 719 funds tracked by Wall St. Rank hold OGN as of Q4 2023.

  • Vantage Consulting Group reported no remaining Organon & Co position as of Q4 2023 after selling out during the quarter.
  • Vantage Consulting Group sold 12,005 Organon & Co shares in Q4 2023, an estimated $208K.
  • Vantage Consulting Group first reported a position in Organon & Co in Q2 2021 and held it in 10 quarters.
  • Vantage Consulting Group's Organon & Co position peaked at $276K in Q4 2021.
  • 719 funds tracked by Wall St. Rank held Organon & Co as of Q4 2023.

Based on Vantage Consulting Group's 13F filing for Q4 2023, filed 14 Feb 2024.